Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines
Open Access
- 23 October 2019
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-15
Abstract
Background: In mammalian cells, Aurora serine/threonine kinases (Aurora A, B, and C) are expressed in a cell cycle-dependent fashion as key mitotic regulators required for the maintenance of chromosomal stability. Aurora-A (AURKA) has been proven to be an oncogene in a variety of cancers; however, whether its expression relates to patient survival and the association with radiotherapy remains unclear in non-small cell lung cancer (NSCLC). Methods: Here, we first analyzed AURKA expression in 63 NSCLC tumor samples by immunohistochemistry (IHC) and used an MTS assay to compare cell survival by targeting AURKA with MLN8237 (Alisertib) in H460 and HCC2429 (P53-competent), and H1299 (P53-deficient) cell lines. The radiosensitivity of MLN8237 was further evaluated by clonogenic assay. Finally, we examined the effect of combining radiation and AURKA inhibition in vivo with a xenograft model and explored the potential mechanism. Results: We found that increased AURKA expression correlated with decreased time to progression and overall survival (p = 0.0447 and 0.0096, respectively). AURKA inhibition using 100 nM MLN8237 for 48 h decreases cell growth in a partially P53-dependent manner, and the survival rates of H460, HCC2429, and H1299 cells were 56, 50, and 77%, respectively. In addition, the survival of H1299 cells decreased 27% after ectopic restoration of P53 expression, and the radiotherapy enhancement was also influenced by P53 expression (DER H460 = 1.33; HCC2429 = 1.35; H1299 = 1.02). Furthermore, tumor growth of H460 was delayed significantly in a subcutaneous mouse model exposed to both MLN8237 and radiation. Conclusions: Taken together, our results confirmed that the expression of AURKA correlated with decreased NSCLC patient survival, and it might be a promising inhibition target when combined with radiotherapy, especially for P53-competent lung cancer cells. Modulation of P53 function could provide a new option for reversing cell resistance to the AURKA inhibitor MLN8237, which deserves further investigation.Keywords
Funding Information
- Natural Science Foundation of Tianjin Municipality (16JCYBJC25300)
- Takeda Pharmaceuticals U.S.A. (080-34000-N16201)
This publication has 72 references indexed in Scilit:
- A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2013
- Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patientsBMC Cancer, 2012
- Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescenceEMBO Molecular Medicine, 2012
- Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiationJournal of Translational Medicine, 2011
- Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer ModelsJournal of Thoracic Oncology, 2011
- Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2Clinical Cancer Research, 2010
- Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer CellsCancer Research, 2008
- Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemiaBlood, 2008
- Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC)Annals of Surgical Oncology, 2007
- Crosstalk between Aurora-A and p53: Frequent Deletion or Downregulation of Aurora-A in Tumors from p53 Null MiceCancer Cell, 2007